The One Line in an AI Stroke-Triage Tool's FDA Clearance That Decides Who Gets Sued
Every AI tool cleared by the FDA to flag a possible brain bleed on a head CT carries the same quiet sentence buried in its labeling: the software triages and notifies, it doesn’t diagnose, and the radiologist who opens the full study is still the one responsible for the read under the existing standard of care. Vendors selling these tools pitch speed - minutes shaved off a stroke workup, a worklist reordered so the most dangerous scan jumps the queue. Hospital risk management and general counsel read the same label and ask a narrower question: what happens on the day the tool works exactly as cleared, and a patient is still harmed by how long a human took to open the study it flagged.
”Triage and notification” is a load-bearing phrase
That phrase isn’t boilerplate - it’s the entire basis on which these tools get a 510(k) clearance instead of the far longer review a diagnostic claim would require. The software reorders a radiologist’s worklist based on a suspected finding; it never tells anyone what’s actually on the scan. That distinction matters enormously once a case goes wrong. If a flagged study still sits unread for forty minutes because every other radiologist on shift is backed up, the hospital’s defense rests on being able to show the alert fired, who received it, and when the study was actually opened - not on whether the AI’s read was correct. A vendor who can’t produce that audit trail, or whose marketing language drifts from “triage aid” into anything that sounds like a diagnosis, hands the hospital’s legal team a worse case than the one they were trying to avoid.
The deal doesn’t close in the emergency department
Outreach into this category tends to target the ED medical director, because that’s who feels the workflow pain of a slow stroke workup most directly. But the ED director doesn’t carry the liability exposure that actually gets a contract signed. The radiology group’s medical director has to sign off because the tool sits inside their PACS and reprioritizes their read queue. Hospital risk management and general counsel have to clear it because the FDA labeling language becomes part of the hospital’s legal defense the first time a flagged case is contested. A pitch that never reaches those two groups stalls at exactly the point where someone finally reads the clearance letter line by line - usually weeks after the ED director was ready to buy.
What a renewal conversation actually checks
A year into using one of these tools, nobody on the hospital side is still asking about sensitivity and specificity numbers from the validation study. They’re asking whether every positive alert gets a documented human review inside a defined time window, whether the audit log can reconstruct exactly what happened on a contested case, and whether the vendor’s indemnification language matches what the clearance actually promises rather than what the sales deck implied. A vendor who can speak to that renewal conversation - in the first outbound email, not after a demo - sounds like they’ve sold into a hospital before. One who’s still leading with accuracy percentages sounds like they haven’t gotten past procurement yet.
The same audit-trail question shows up one layer over in diagnostic imaging throughput software sold to outpatient centers, though the stakes and the buyer are different - throughput software answers to an operations director worried about scanner utilization, not to risk management worried about a missed bleed. Vendors selling anywhere into the broader healthcare and life sciences market run into the same pattern: the department that feels the pain first is rarely the one who actually signs.
Talk to us if your outbound into hospital AI triage tools is still pitching speed to the ED when it’s radiology leadership and risk management who actually clear the deal.